International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-1 doi: 10.5281/zenodo.13349258
Original Research Article
Role of Corrected Count Increment (CCI) As A Surrogate Marker for Efficacy of Platelet Concentrate Transfusions- A Hospital Based Study
Published
Jan. 25, 2025
Abstract

Introduction: Platelet transfusion is a lifesaving procedure for thrombocytopenia, can be either prophylactic or therapeutic. Evaluation of the response to platelet transfusion by calculating Corrected count increment (CCI).The corrected count increment (CCI) is a laboratory evaluation of the effectiveness of Platelet concentrate transfusion. Corrected count increment (CCI) is the most widely used surrogate marker for evaluating refractory patient’s responses to platelet component transfusions which is measured at 24 hour post transfusion.Aim and Objectives: 1) To study the number of platelet transfusion that was done during the study period. 2) To study the indications for the platelet concentrate transfusions in cases of thrombocytopenia. 3) To evaluate efficacy of platelet concentrate transfusion for increment of platelet count. 4) To evaluate the causes of refractoriness to platelet transfusion. Material and Methods:The present study included 100 cases having thrombocytopeniaadmittedat SMIMER hospital whoreceived platelet concentrate transfusion during the study period from 1st June 2024 to 31st November 2024.Patient information was collected from blood bank component register and from ward.Investigations including pre and post transfusion platelet counts were noted using following formula, Results: Majority of the platelet recipient were transfused prophylactically when platelet count were > 20000/ul. The most common among them is infectious causes. The most common category of diagnosis among these patients was infectious agent. Conclusion: The usage of platelet concentrates in thrombocytopenia found in the study reveals infectious cause as predominant and common finding.CCI values is found to be useful in evaluating response in cases of thrombocytopenic patients receiving platelet concentrate transfusion.It was noticed that platelet count does not increase to the expected level after platelet transfusions in certain patients due to refractoriness to the platelet transfusion (in cases of fever, sepsis etc).

Recommended Articles
Loading Image...
Volume-6, Issue-1
Citations
2426 Views
322 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved